A Randomized, Controlled Dose-finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-positive Adults

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2013 Oct 22

PMID 24142232

Citations 42

Authors

Jaime Montoya

Juan Antonio Solon

Soledad Rosanna C Cunanan

Luz Acosta

Anne Bollaerts

Philippe Moris

Michel Janssens

Erik Jongert

Marie-Ange Demoitie

Pascal Mettens

Salvacion Gatchalian

Carlota Vinals

Joe Cohen

Opokua Ofori-Anyinam

Affiliations

Soon will be listed here.

Abstract

Purpose: In this dose-finding Phase II study (NCT00621322), we evaluated the safety and immunogenicity of different formulations of the candidate tuberculosis vaccine containing the M72 antigen (10/20/40 μg doses) and the liposome-based AS01 Adjuvant System. We aimed to select the lowest-dose combination of M72 and AS01 that was clinically well tolerated with immunogenicity comparable to that of the previously tested M72/AS01B (40 μg) candidate vaccine.

Methods: Healthy PPD-positive (induration 3-10 mm) adults (18-45 years) in The Philippines were randomized (4:4:4:4:1:1) to receive 2 injections, 1 month apart, of M72/AS01B (40 μg), M72/AS01E (10 μg), M72/AS01E (20 μg), M72/AS02D (10 μg), M72/Saline (40 μg) or AS01B alone, and were followed up for 6 months. AS01E and AS02D contain half the quantities of the immunostimulants present in AS01B. AS02D is an oil-in-water emulsion. Vaccine selection was based on the CD4(+) T-cell responses at 1 month post vaccination.

Results: All formulations had a clinically acceptable safety profile with no vaccine-related serious adverse events reported. Two vaccinations of each adjuvanted M72 vaccine induced M72-specific CD4(+) T-cell and humoral responses persisting at 6 months post vaccination. No responses were observed with AS01B alone. One month post second vaccination, CD4(+) T-cell responses induced by each of the three M72/AS01 vaccine formulations were of comparable magnitudes, and all were significantly higher than those induced by M72/AS02D (10 μg) and M72/Saline.

Conclusions: The formulation with the lowest antigen and adjuvant dose, M72/AS01E (10 μg), fulfilled our pre-defined selection criteria and has been selected for further clinical development.

Citing Articles

analysis for the development of multi-epitope vaccines against .

Yun J, Kim A, Kim S, Shin E, Ha S, Kim D Front Immunol. 2024; 15:1474346.

PMID: 39624097 PMC: 11609213. DOI: 10.3389/fimmu.2024.1474346.

Tuberculosis Vaccines and T Cell Immune Memory.

Li F, Dang W, Du Y, Xu X, He P, Zhou Y Vaccines (Basel). 2024; 12(5).

PMID: 38793734 PMC: 11125691. DOI: 10.3390/vaccines12050483.

Optimizing antigen selection for the development of tuberculosis vaccines.

Yang Y, Chen Y, Xia T Cell Insight. 2024; 3(3):100163.

PMID: 38572176 PMC: 10987857. DOI: 10.1016/j.cellin.2024.100163.

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against challenge.

Stylianou E, Pinpathomrat N, Sampson O, Richard A, Korompis M, McShane H Front Immunol. 2023; 14:1263457.

PMID: 37869008 PMC: 10585038. DOI: 10.3389/fimmu.2023.1263457.

Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines.

Kim H, Choi H, Shin S Front Immunol. 2023; 14:1193058.

PMID: 37638056 PMC: 10451085. DOI: 10.3389/fimmu.2023.1193058.

References

Doherty T, Kastelein R, Menon S, Andrade S, Coffman R . Modulation of murine macrophage function by IL-13. J Immunol. 1993; 151(12):7151-60. View

Beveridge N, Price D, Casazza J, Pathan A, Sander C, Asher T . Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol. 2007; 37(11):3089-100. PMC: 2365909. DOI: 10.1002/eji.200737504. View

Aagaard C, Hoang T, Vingsbo-Lundberg C, Dietrich J, Andersen P . Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol. 2009; 183(4):2659-68. DOI: 10.4049/jimmunol.0900947. View

Rook G, Dheda K, Zumla A . Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Tuberculosis (Edinb). 2006; 86(3-4):152-62. DOI: 10.1016/j.tube.2006.01.018. View

Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitie M, Mettens P . Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2012; 31(17):2196-206. DOI: 10.1016/j.vaccine.2012.05.035. View

Flynn J, Chan J . Immunology of tuberculosis. Annu Rev Immunol. 2001; 19:93-129. DOI: 10.1146/annurev.immunol.19.1.93. View

Fine P . Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995; 346(8986):1339-45. DOI: 10.1016/s0140-6736(95)92348-9. View

Sander C, Pathan A, Beveridge N, Poulton I, Minassian A, Alder N . Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med. 2009; 179(8):724-33. PMC: 2858810. DOI: 10.1164/rccm.200809-1486OC. View

Mueller H, Detjen A, Schuck S, Gutschmidt A, Wahn U, Magdorf K . Mycobacterium tuberculosis-specific CD4+, IFNgamma+, and TNFalpha+ multifunctional memory T cells coexpress GM-CSF. Cytokine. 2008; 43(2):143-8. DOI: 10.1016/j.cyto.2008.05.002. View

10.

Dillon D, Alderson M, Day C, Lewinsohn D, Coler R, Bement T . Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun. 1999; 67(6):2941-50. PMC: 96604. DOI: 10.1128/IAI.67.6.2941-2950.1999. View

11.

Caccamo N, Guggino G, Joosten S, Gelsomino G, Di Carlo P, Titone L . Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol. 2010; 40(8):2211-20. DOI: 10.1002/eji.201040455. View

12.

Djuardi Y, Sartono E, Wibowo H, Supali T, Yazdanbakhsh M . A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses. PLoS One. 2010; 5(11):e14066. PMC: 2988815. DOI: 10.1371/journal.pone.0014066. View

13.

Aagaard C, Hoang T, Izzo A, Billeskov R, Troudt J, Arnett K . Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One. 2009; 4(6):e5930. PMC: 2691953. DOI: 10.1371/journal.pone.0005930. View

14.

Hammarlund E, Lewis M, Hansen S, Strelow L, Nelson J, Sexton G . Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003; 9(9):1131-7. DOI: 10.1038/nm917. View

15.

Hoang T, Nansen A, Roy S, Billeskov R, Aagaard C, Elvang T . Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. PLoS One. 2009; 4(6):e5928. PMC: 2691482. DOI: 10.1371/journal.pone.0005928. View

16.

Young J, Adetifa I, Ota M, Sutherland J . Expanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatment. PLoS One. 2010; 5(6):e11237. PMC: 2888639. DOI: 10.1371/journal.pone.0011237. View

17.

Finan C, Ota M, Marchant A, Newport M . Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants. PLoS One. 2008; 3(10):e3485. PMC: 2567029. DOI: 10.1371/journal.pone.0003485. View

18.

Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M . Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med. 2005; 11(10):1118-24. DOI: 10.1038/nm1292. View

19.

Rook G, Dheda K, Zumla A . Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol. 2005; 5(8):661-7. DOI: 10.1038/nri1666. View

20.

Spertini F, Audran R, Lurati F, Ofori-Anyinam O, Zysset F, Vandepapeliere P . The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb). 2012; 93(2):179-88. DOI: 10.1016/j.tube.2012.10.011. View